Peoples Bank KS trimmed its position in GSK plc (NYSE:GSK – Free Report) by 47.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,045 shares of the pharmaceutical company’s stock after selling 4,525 shares during the quarter. Peoples Bank KS’s holdings in GSK were worth $171,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in GSK. FMR LLC boosted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Primecap Management Co. CA lifted its holdings in shares of GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after purchasing an additional 1,773,020 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of GSK in the second quarter worth $52,487,000. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its position in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.
GSK Trading Up 0.4 %
NYSE:GSK opened at $34.11 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market capitalization of $70.69 billion, a P/E ratio of 22.15, a P/E/G ratio of 1.52 and a beta of 0.63. The stock’s 50 day moving average price is $34.59 and its 200 day moving average price is $38.30. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92.
GSK Increases Dividend
Analyst Upgrades and Downgrades
GSK has been the subject of a number of research reports. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.
Check Out Our Latest Stock Analysis on GSK
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- Stock Splits, Do They Really Impact Investors?
- U.S. Markets to Close for Jimmy Carter National Day of Mourning
- What Does Downgrade Mean in Investing?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.